Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings
Blood · 2023
DOI: 10.1182/blood.2022017686 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Jacqueline S Garcia und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Two articles in this week’s issue focus on the use of ipilimumab and decitabine for patients with myelodysplasia (MDS) and acute myeloid leukemia (AML) before and after hematopoietic stem cell transplantation (HSCT) for high-risk disease. In the first article, Garcia et al report on the results of a phase 1 trial of the combination in 54 patients, demonstrating overall response rate of 52% in patients who are HSCT-naïve and 20% in patients post-HSCT; responses are usually short-lived. In the second article, Penter and colleagues characterize gene expression responses to therapy and conclude that decitabine acts directly to clear leukemic cells while ipilimumab acts on infiltrating lymphocytes in marrow and extramedullary sites. Responses are determined by leukemic cell burden and by the frequency and phenotype of infiltrating lymphocytes. Increasing bone marrow regulatory T cells is identified as a potential contributor to checkpoint inhibitor escape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
- Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
- Division of Hematology/Oncology, University of Virginia, Charlottesville, VA.
- Department of Hematology/Oncology, Case Comprehensive Cancer Center, Cleveland, OH.
- Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA.
- Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
ORCID-Profile: Jacqueline S Garcia, Livius Penter, Paul Koller, Brian A Jonas, Marlise R Luskin, Eric S Winer, Jerome Ritz, Catherine J Wu, Daniel J DeAngelo
Förderung
- NCI NIH HHS
Zitieren
APA
Garcia, J. S., Flamand, Y., Penter, L., Keng, M., Tomlinson, B. K., Mendez, L. M., Koller, P., Cullen, N., Arihara, Y., Pfaff, K., Wolff, J. O., Brunner, A. M., Galinsky, I., Bashey, A., Antin, J. H., Cutler, C., Ho, V., Jonas, B. A., Luskin, M. R., …, & Soiffer, R. J. (2023). Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood. https://doi.org/10.1182/blood.2022017686
Vancouver
Garcia JS, Flamand Y, Penter L, Keng M, Tomlinson BK, Mendez LM, et al. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood. 2023. doi:10.1182/blood.2022017686
BibTeX
@article{Garcia2023,
author = {Garcia, Jacqueline S and Flamand, Yael and Penter, Livius and Keng, Michael and Tomlinson, Benjamin K and Mendez, Lourdes M and Koller, Paul and Cullen, Nicole and Arihara, Yohei and Pfaff, Kathleen and Wolff, Jacquelyn O and Brunner, Andrew M and Galinsky, Ilene and Bashey, Asad and Antin, Joseph H and Cutler, Corey and Ho, Vincent and Jonas, Brian A and Luskin, Marlise R and Wadleigh, Martha and Winer, Eric S and Savell, Alexandra and Leonard, Rebecca and Robertson, Taylor and Davids, Matthew S and Streicher, Howard and Rodig, Scott J and Ritz, Jerome and Wu, Catherine J and DeAngelo, Daniel J and Neuberg, Donna and Stone, Richard M and Soiffer, Robert J},
title = {Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022017686}
}
EUVIMED